Abstract
Despite the multidimensional value of implementing genomic medicine, in terms of diagnostic yield, cost-effectiveness, and optimisation of care trajectories, its deployment in many African countries, including Algeria, remains constrained by major structural and interpretive challenges, compounded by the persistent underrepresentation of African populations in genomic databases with direct consequences for variant interpretation and clinical decision-making.
We implemented a fully in-house whole-exome sequencing (WES) workflow structured through a clinically driven sequential framework in 14 unrelated patients with unexplained neurodevelopmental disorders, in a context of high consanguinity and enriched recessive inheritance. A definitive molecular diagnosis was established in 8 cases, with pathogenic or likely pathogenic variants identified in MECP2, PTPN11, FOXG1, ARV1, GNAO1, ATM, ROBO3, and CHD3. Five cases yielded variants of uncertain significance and one clinically relevant incidental finding was identified.
Beyond its diagnostic contribution, this study reveals persistent interpretive limitations: a disproportionate VUS burden, complex incidental finding management, and reduced accessibility to classification criteria, reflecting database underrepresentation, the predominance of private variants, and the limits of current frameworks in consanguineous settings. These findings underscore the necessity of population-specific reference datasets, iterative phenotyping, adapted ethical frameworks, and strategies addressing territorial disparities in access.
This work demonstrates that WES implementation requires a structured multidisciplinary ecosystem integrating clinical, bioinformatic, and ethical dimensions, and provides a transferable model for the sustainable integration of genomic medicine in under-resourced settings, while highlighting the global scientific value of incorporating underrepresented populations into genomic research.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Ministry of Higher Education and Scientific Research of Algeria. The funding body had no role in the design of the study, data collection, analysis, interpretation, or writing of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was granted by the National Ethics Committee for Health, Algeria, on January 14, 2026 (approval number: 2026-02). Written informed consent for genetic testing and publication was obtained from all participants or their legal guardians, in accordance with national regulations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
